アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptide within Human Angiotensinogen aa 400-500 (internal sequence). The exact sequence is proprietary.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab108334 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 53 kDa.
Block with 5% BSA
|IP||1/10 - 1/100.|
|ICC/IF||1/100 - 1/250.|
Ab108334 targeting angiotensinogen in various mouse, rat and human tissues (see lane descriptions).
Blocking buffer for the first lanes 1-5: 5% NFDM/TBST; the second lanes 1-5: BSA/TBST.
Lane 1 blocking buffer: NFDM/TBST
Lane 2 blocking buffer: BSA/TBST
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"